Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

742.70INR
3:57pm IST
Change (% chg)

Rs5.65 (+0.77%)
Prev Close
Rs737.05
Open
Rs737.00
Day's High
Rs745.95
Day's Low
Rs735.30
Volume
243,152
Avg. Vol
307,753
52-wk High
Rs933.70
52-wk Low
Rs706.40

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.28
Market Cap(Mil.): Rs1,771,010.00
Shares Outstanding(Mil.): 2,406.75
Dividend: 1.00
Yield (%): 0.14

Financials

  SUN.BO Industry Sector
P/E (TTM): 28.69 36.94 36.87
EPS (TTM): 25.65 -- --
ROI: -- 14.36 13.86
ROE: -- 15.19 14.81

MEDIA-Indian court orders Sun Pharma to cough up pending wages - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

29 Sep 2016

EU court to rule on drugmaker Lundbeck's pay-for-delay deals

BRUSSELS, Sept 6 Europe's top court will rule on Thursday whether Danish drugmaker Lundbeck breached EU antitrust rules by paying smaller rivals to delay generic copies of its blockbuster citalopram anti-depressant from entering the market.

06 Sep 2016

Sun Pharma first-quarter profit boosted by Gleevec generic

MUMBAI Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.

12 Aug 2016

India's Sun Pharma Q1 profit boosted by Gleevec generic

MUMBAI, Aug 12 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States.

12 Aug 2016

BUZZ-India's Sun Pharma rises on U.S. FDA nod for generic diabetes drug

** Sun Pharmaceutical Industries rises as much as 1.4 pct after the drugmaker gets approval from U.S. health regulators for its generic version of Glumetza tablets, which treat type 2 diabetes

02 Aug 2016

BUZZ-India's Sun Pharma up; Co signs licence deal for Psoriasis treatment

** Shares of Indian drugmaker Sun Pharmaceutical Industries rise as much as 2.36 pct to their highest in nearly two months

28 Jul 2016

Exclusive: Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.

26 Jul 2016

Teva, Mylan eye Pfizer's Brazil venture, sources say

SAO PAULO Teva Pharmaceutical Industries Ltd and Mylan NV have shown preliminary interest in a Brazilian generic drugmaking joint-venture in which Pfizer Inc has a 40 percent stake, two people familiar with the process said.

26 Jul 2016

BUZZ-India's Sun Pharma down; gains in early trade on share buyback

** Shares of Sun Pharmaceutical Industries rise as much as 1.65 pct in early trade, but down 0.5 pct as of 0552 GMT

24 Jun 2016

India's Sun Pharma enters dermatology segment to expand retail offering

MUMBAI, June 8 India's Sun Pharmaceutical Industries Ltd said on Wednesday it had entered the dermatology segment as part of an initiative to further expand its retail offerings.

08 Jun 2016

Earnings vs. Estimates